898537-77-4

Basic information

• Product Name: 3-TERT-BUTYL-1-(3-METHYLPHENYL)-1H-PYRAZOL-5-AMINE
• Synonyms: 3-TERT-BUTYL-1-(3-METHYLPHENYL)-1H-PYRAZOL-5-AMINE;5-TERT-BUTYL-2-M-TOLYL-2H-PYRAZOL-3-YLAMINE;3-(tert-Butyl)-1-(M-tolyl)-1H-pyrazol-5-aMine;1H-Pyrazol-5-aMine,3-(1,1-diMethylethyl)-1-(3-Methylphenyl)-;3-(1,1-Dimethylethyl)-1-(3-methylphenyl)-1H-pyrazol-5-amine
• CAS NO: 898537-77-4
• Molecular Formula: C₁₄H₁₉N₃
• Molecular Weight: 229.32
• Mol File: 898537-77-4.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 3-TERT-BUTYL-1-(3-METHYLPHENYL)-1H-PYRAZOL-5-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-TERT-BUTYL-1-(3-METHYLPHENYL)-1H-PYRAZOL-5-AMINE(898537-77-4)
• EPA Substance Registry System: 3-TERT-BUTYL-1-(3-METHYLPHENYL)-1H-PYRAZOL-5-AMINE(898537-77-4)

Safety Data

• Hazardous Substances Data: 898537-77-4(Hazardous Substances Data)

Usage

General Description

3-Tert-butyl-1-(3-methylphenyl)-1H-pyrazol-5-amine is a chemical compound with a molecular formula C13H18N4. It is a pyrazole derivative that contains a tert-butyl group and a 3-methylphenyl group. 3-TERT-BUTYL-1-(3-METHYLPHENYL)-1H-PYRAZOL-5-AMINE has potential applications in the field of pharmaceuticals and agrochemicals due to its biological activity. It may be used as a building block in the synthesis of various organic compounds with desired properties. Its specific uses and properties can vary depending on the context and intended application.

Upstream product

• 59997-51-2 trimethylacetylacetonitrile 
• 637-04-7 (3-methylphenyl)hydrazine hydrochloride 
• 536-89-0 m-tolylhydrazine 

Downstream Products

• 1160934-76-8 2,2,2-trichloroethyl (3-(tert-butyl)-1-(m-tolyl)-1H-pyrazol-5-yl)carbamate 
• 1486470-38-5 N-(3-t-butyl-1-m-tolyl-1H-pyrazol-5-yl)-2-oxo-2-phenylacetamide 
• 1486470-39-6 N-(3-t-butyl-1-m-tolyl-1H-pyrazol-5-yl)-2-oxo-2-p-tolylacetamide 
• 1486470-40-9 N-(3-t-butyl-1-m-tolyl-1H-pyrazol-5-yl)-2-(4-chlorophenyl)-2-oxoacetamide 
• 1071964-66-3 1-(3-tert-butyl-1-m-tolyl-1H-pyrazol-5-yl)-3-(5-(2-morpholinoethoxy)-2H-chromen-8-yl)urea 
• 1071964-34-5 1-(3-tert-butyl-1-m-tolyl-1H-pyrazol-5-yl)-3-(5-(2-morpholinoethoxy)chroman-8-yl)urea 
• 876299-08-0 1-[3-tert-butyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-3-(2-{[3-(3-chloro-2-hydroxyphenyl)[1,2,4]triazolo[4,3-a]pyridin-6-yl]thio}benzyl)urea 
• 1344738-26-6 1-[2-({3-[2-(benzyloxy)-3-chlorophenyl][1,2,4]triazolo[4,3-a]pyridin-6-yl}thio)benzyl]-3-[3-tert-butyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]urea 
• 1163730-91-3 1-(3-tert-butyl-1-m-tolyl-1H-pyrazol-5-yl)-3-(4-chlorophenyl)urea 
• 898537-79-6 1-(5-tert-Butyl-2-m-tolyl-2H-pyrazol-3-yl)-3-[4-(6-chloro-pyrimidin-4-yloxy)-3-methoxy-phenyl]-urea 

Relevant articles and documents

Biophysical investigation and conformational analysis of p38α kinase inhibitor doramapimod and its analogues

Doramapimod (BIRB 796) is a potent inhibitor of p38α mitogen-activated protein kinase. It contains an aryl-pyrazole scaffold as a pharmacophore critical for binding. The aryl-pyrazole scaffold is not planar and adopts an out-of-plane conformation, which is described by the torsion angle θ. In this letter, we report the chemical synthesis and biophysical characterization of different analogues of doramapimod (3-12) exhibiting distinctly different aryl-pyrazole torsion angle θ values. The torsion angle θ values of the synthesized analogues (3-6) were determined by crystal structural analysis and the binding affinities to p38α kinase investigated by microscale thermophoresis. Our results unveil a clear correlation between kinase binding and the torsion angle θ of tested doramapimod analogues, highlighting the importance of inhibitor conformation for protein binding.

Synthesis and Biological Evaluation of Chromenylurea and Chromanylurea Derivatives as Anti-TNF-a agents that Target the p38 MAPK Pathway

A series of 1-aryl-3-(2H-chromen-5-yl)urea and 1-aryl-3-(chroman-5-yl)urea derivatives were designed, synthesized and evaluated for their inhibitory activities towards TNF-a production in lipopolysaccharide-stimulated THP-1 cells. The most active compound, 40g, inhibited TNF-a release with an IC50 value of 0.033 μM, which is equipotent to that of BIRB796 (IC50 = 0.032 μM).

Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc

The emergence of drug resistance remains a fundamental challenge in the development of kinase inhibitors that are effective over long-term treatments. Allosteric inhibitors that bind to sites lying outside the highly conserved ATP pocket are thought to be more selective than ATP-competitive inhibitors and may circumvent some mechanisms of drug resistance. Crystal structures of type I and allosteric type III inhibitors in complex with the tyrosine kinase cSrc allowed us to employ principles of structure-based design to develop these scaffolds into potent type II kinase inhibitors. One of these compounds, 3c (RL46), disrupts FAK-mediated focal adhesions in cancer cells via direct inhibition of cSrc. Details gleaned from crystal structures revealed a key feature of a subset of these compounds, a surprising flexibility in the vicinity of the gatekeeper residue that allows these compounds to overcome a dasatinib-resistant gatekeeper mutation emerging in cSrc.